Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.[ Read More ]
The intrinsic value of one IMTXW stock under the base case scenario is HIDDEN Compared to the current market price of 0.6 USD, immatics biotechnologies GmbH is HIDDEN
Price Chart IMTXW
| Current Assets | 449 M |
| Cash & Short-Term Investments | 426 M |
| Receivables | 5.74 M |
| Other Current Assets | 17.7 M |
| Non-Current Assets | 60.6 M |
| Long-Term Investments | 0 |
| PP&E | 57.1 M |
| Other Non-Current Assets | 3.54 M |
| Current Liabilities | 157 M |
| Accounts Payable | 7.67 M |
| Short-Term Debt | 2.6 M |
| Other Current Liabilities | 146 M |
| Non-Current Liabilities | 128 M |
| Long-Term Debt | 12.8 M |
| Other Non-Current Liabilities | 116 M |
| Revenue | 54 M |
| Cost Of Revenue | 119 M |
| Gross Profit | -64.7 M |
| Operating Expenses | 156 M |
| Operating Income | -102 M |
| Other Expenses | -4.73 M |
| Net Income | -97 M |
| Net Income | -97 M |
| Depreciation & Amortization | 7.23 M |
| Capital Expenditures | -31 M |
| Stock-Based Compensation | 20.7 M |
| Change in Working Capital | 81.6 M |
| Others | 71.6 M |
| Free Cash Flow | -12.7 M |
| Date | Value | Insider | Amount | Avg Price |
|---|
immatics biotechnologies GmbH IMTXW